Janssen Pharmaceutica Nv

Astex Therapeutics Limited

Jayaprakash Karkera

Suso Jesus Platero

Matthew V Lorenzi

Deborah Ricci

Weimin Li

Michael Schaffer

Deborah Sokol Ricci

Michael Gormley

Raluca Verona

Disclosed herein are methods of identifying a cancer patient that will be responsive to treatment with a fibroblast growth factor receptor (FGFR) inhibitor and methods of treating cancer patients. The methods involve evaluating a biological sample from the patient for the presence of one or more FGFR mutants from a FGFR mutant gene panel. Kits and primers for identifying the presence of one or more FGFR mutant genes in a biological sample are also disclosed herein.

Use of FGFR mutant gene panels in identifying cancer patients that will be responsive to treatment with an FGFR inhibitor

Provided herein are methods of predicting a likelihood of survival following treatment with AA and prednisone in a patient having CRPC.

Biological markers for identifying patients for treatment with abiraterone acetate

Provided herein are combination therapies for the treatment of cancer. In particular, the disclosed methods are directed to treatment of cancer in a patient comprising administering an antibody that blocks the interaction between PD-1 and PD-L1 and an FGFR inhibitor, wherein the antibody that blocks the interaction between PD-1 and PD-L1 and the FGFR inhibitor are administered if one or more FGFR variants are present in a biological sample from the patient.

FGFR/PD-1 combination therapy for the treatment of cancer

The present invention provides assays for detecting presence or quantity of multiple biomarkers in one biological sample.

Growing community of inventors

Germantown, MD, United States of America

Jayaprakash Karkera